检索结果-南通市图书馆

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study

World Journal of Gastrointestinal Oncology 2020年第2期12卷 182-194页

作者： In Rae Cho Huapyong Kang Jung Hyun Jo Hee Seung Lee Moon Jae Chung Jeong Youp Park Seung Woo Park Si Young Song chansik an Mi-Suk Park Seungmin Bang Department of Internal Medicine International Saint Mary’s HospitalCatholic Kwandong University College of MedicineIncheon 22711South Korea Department of Medicine Yonsei University Graduate School50-1 Yonsei-roSeoul 03722South Korea Division of Gastroenterology Department of Internal MedicineYonsei University College of Medicine50-1 Yonsei-roSeoul 03722South Korea Department of Radiology Yonsei University College of Medicine50-1 Yonsei-roSeoul 03722South Korea

BACKGROUND FOLFIRINOX and gemcitabine plus nab-paclitaxel(Gem+nabPTX)were recently introduced for metastatic pancreatic cancer ***,studies that compared these two regimens and studies in Asian populations are *** To compare the treatment outcomes of FOLFIRINOX and Gem+nabPTX regimen for metastatic pancreatic cancer treatment in Korean *** Patients with metastatic or recurrent pancreatic cancer treated with FOLFIRINOX(n=86)or Gem+nabPTX(n=81)as the first-line since January 2015 were identified using the Severance Hospital Pancreatic Cancer Cohort *** efficacy,treatment-related adverse events and economic aspects were *** Patients in the FOLFIRINOX group were significantly younger(54 vs 65 years;P<0.001)and had better performance statuses at *** median overall survival(10.7 vs 12.1 mo;P=0.157),progression-free survival(8.0 vs 8.4 mo;P=0.134),and objective response rates(33.7%vs 46.9%;P=0.067)were not significantly different when compared with Gem+nabPTX ***≥3 neutropenia and gastrointestinal adverse events were more common in the FOLFIRINOX *** drug costs of both regimens were *** Treatment efficacy and economic burdens were comparable between the two ***,the details of adverse event were ***+nabPTX regimen might be considered preferentially in certain conditions.

关键词： Pancreatic cancer Chemotherapy FOLFIRINOX Gemcitabine Nabpaclitaxel Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：